SCHEMBL5354972

SCHEMBL5354972

O=c1[nH]nc2c(NCCNc3cc(CN4CCOCC4)ccn3)nc3ccc(F)cc3n12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.42
PDE2A O00408 3/20 0.41
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
IDO2 Q6ZQW0 1/20 0.38
CDK1 P06493 2/20 0.37
CDK2 P24941 2/20 0.37
CASP3 P42574 1/20 0.37
CDK9 P50750 1/20 0.37
CASP7 P55210 1/20 0.37
CHEK1 O14757 1/20 0.37
KDR P35968 1/20 0.36
PDE5A O76074 1/20 0.36
TBK1 Q9UHD2 2/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
PLK1 P53350 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361972 0.79 ADORA1 (0.53) ADORA1PDE2ACDK9
SCHEMBL5356548 0.79 ADORA1 (0.47) ADORA1PIK3CA
SCHEMBL5359423 0.75 SYK (0.46) ADORA1PDE2ACHEK1
SCHEMBL5357503 0.75 ADORA1 (0.54) ADORA1CDK1CDK2CDK9AURKB
SCHEMBL5355548 0.74 ADORA1 (0.46) ADORA1PLK1
SCHEMBL5356547 0.74 ADORA1 (0.54) ADORA1KDM4ESMN1; SMN2
SCHEMBL5359569 0.73 ADORA1 (0.53) ADORA1
SCHEMBL5362434 0.73 ADORA1 (0.77) ADORA1MAPK8PLK1KDM4ESMN1; SMN2
SCHEMBL5367611 0.73 ADORA1 (0.44) ADORA1
SCHEMBL5349980 0.73 ADORA1 (0.48) ADORA1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202245-B2 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. (US) 2007-04-10 US claimed
EP-1613629-A1 SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES Pfizer Products Inc. (US) 2006-01-11 EP claimed
WO-2004085439-A1 SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES PFIZER PRODUCTS INC. (US) 2004-10-07 WO claimed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 ADORA1 12/4885PDE2A 342/4885IDO1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.